Skip to main content

Table 2 Safety evaluation

From: A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

Patient no. Toxicity of HF10 DLT Evaluation (CTCAE ver 4.0)
Cohort 1 HF-1-02 (−) (−) Grade III Neutrophil and Platlet count decrease, Duodenal stenosis, Perforative peritonitis
HF-1-04 (−) (−) Grade II fever, Blood bilirubin increase (stent failure), Interstitial pneumonia (After treatment)
HF-1-05 (−) (−) NA
Cohort 2 HF-2-01 (−) (−) Grade III Neutrophil decrease
HF-2-02 (−) (−) Grade III Neutrophil decrease
HF-2-03 (−) (−) Grade III Neutrophil decrease and Grade II ALT increase
Cohort 3 HF-3-01 (−) (−) Grade IV Hepatobiliary disorder
HF-3-02 (−) (−) NA
HF-3-03 (−) (−) NA
HF-3-04 (−) (−) Grade III Neutrophil decrease
  1. DLT dose-limiting toxicity